high credibilityU.S. Food and Drug Administration2015
FDA approval letter: evolocumab (Repatha)
FDA
accessdata.fda.gov
high credibilitySource scorecard — credibility, citation history, and editorial transparency for this domain.
3
Citations
3
High credibility
0
Medium credibility
2
Theory pages
Cited-theory verdict breakdown
Debunked
1
Unproven
1
Theory coverage
high credibilityFDA2024
FDA: FAERS adverse event database — semaglutide
FDA CDER
high credibilityFDA2023
FDA label: Ozempic full prescribing information
FDA CDER